81P Safety and effectiveness of apalutamide for the treatment of non-metastatic castration-resistant prostate cancer (nm-CRPC): Preliminary results from an open-label expanded access protocol (EAP)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.2077 ◽

2021 ◽

Vol 32 ◽

pp. S1370

Author(s):

S. Campos-Gomez ◽

J.C. Ochoa ◽

F. Cruz ◽

A. Mota ◽

M.A.J. Rios ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Preliminary Results ◽

Expanded Access ◽

Castration Resistant

Download Full-text

Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5061 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5061-5061

Author(s):

Cora N. Sternberg ◽

Gedske Daugaard ◽

Lajos Geczi ◽

Sebastien J. Hotte ◽

Paul N. Mainwaring ◽

...

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70417-6 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1263-1268 ◽

Author(s):

Cora N Sternberg ◽

Daniel Castellano ◽

Gedske Daugaard ◽

Lajos Géczi ◽

Sebastien J Hotte ◽

...

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

Expanded access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer post-chemotherapy – results in Czech Republic

European Urology Supplements ◽

10.1016/s1569-9056(16)30243-3 ◽

2016 ◽

Vol 15 (11) ◽

pp. e1394

Author(s):

T. Hradec ◽

O. Capoun ◽

R. Sobotka ◽

M. Pesl ◽

V. Soukup ◽

...

Keyword(s):

Prostate Cancer ◽

Czech Republic ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Expanded Access ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.5686956.10860058 ◽

2011 ◽

Author(s):

Cora Sternberg ◽

Linda Cerbone

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Docetaxel Treatment ◽

Open Label Trial

Download Full-text

A Phase 2, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.07.013 ◽

2021 ◽

Author(s):

Nobuaki Matsubara ◽

Hirotsugu Uemura ◽

Satoshi Nagamori ◽

Hiroyoshi Suzuki ◽

Hiroji Uemura ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739562946.793583755 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Phase 2 Trial ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)

Annals of Oncology ◽

10.1093/annonc/mdy284.068 ◽

2018 ◽

Vol 29 ◽

pp. viii301

Author(s):

J.S. de Bono ◽

C. Higano ◽

F. Saad ◽

K. Miller ◽

M. Casey ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Hormonal Therapy ◽

Response Rate ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Download Full-text

Faculty Opinions recommendation of Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732320563.793553396 ◽

2018 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Androgen Therapy ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

S54 PRELIMINARY RESULTS OF ABIRATERONE ACETATE TREATMENT IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER

European Urology Supplements ◽

10.1016/s1569-9056(13)60248-1 ◽

2012 ◽

Vol 11 (4) ◽

pp. 145-146

Author(s):

T.E. Sener ◽

T. Top ◽

I. Tinay ◽

L. Turkeri

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Preliminary Results ◽

Castration Resistant

Download Full-text